文献速递MDS 与骨髓增殖性肿瘤白血病造血干细胞移植与细胞治疗

慢性粒单核细胞白血病2020年诊断、风险分层与管理更新

Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.
PubMed 文献 · Am J Hematol · 2020-01-01

本文概述慢性粒单核细胞白血病(CMML)为克隆性造血干细胞疾病,兼具骨髓增生异常综合征与骨髓增殖性肿瘤特征,3-5年白血病转化风险约15%。诊断基于持续单核细胞增多及骨髓发育异常,分子整合预后模型如MMM可分层生存,低甲基化药物常用但完全缓解率有限,异基因移植为唯一可能治愈手段。

要点

  • 诊断需持续>3个月外周血单核细胞≥1×10^9/L且单核细胞≥10%,伴骨髓发育异常。
  • MMM模型纳入ASXL1无义/移码突变、单核细胞>10×10^9/L等5项风险因素。
  • 低甲基化药物总反应率约40%-50%,完全缓解率约7%-17%。

核心结论

  • CMML是克隆性造血干细胞疾病,具有白血病转化风险,需分子整合模型进行风险分层并指导治疗。

研究设计与样本

  • 本文为2020年CMML诊断、风险分层与管理的更新综述,未报告系统检索范围。

主要发现

  • 约30%患者存在克隆性细胞遗传学异常,>90%存在基因突变。
  • TET2突变约60%,SRSF2约50%,ASXL1约40%,RAS通路约30%。
  • ASXL1和DNMT3A突变及TET2突变缺失对总生存有负面影响。
  • MMM将患者分为高危(≥3个风险因素)、中危-2(2个)、中危-1(1个)和低危(0个),中位生存分别为16、31、59和97个月。

关键数值与推荐

  • 诊断标准:持续>3个月外周血单核细胞增多(≥1×10^9/L;单核细胞≥10%),伴骨髓发育异常。
  • MMM风险因素:ASXL1无义或移码突变、绝对单核细胞计数>10×10^9/L、血红蛋白<10 g/dL、血小板计数<100×10^9/L、外周血幼稚髓系细胞。
  • 低甲基化药物(如5-氮杂胞苷和地西他滨)总反应率约40%-50%,完全缓解率约7%-17%,对突变等位基因负荷无影响。

临床怎么用

  • 采用分子整合预后模型(GFM、MMM、CPSS-Mol)进行风险分层。
  • 低甲基化药物常用,但完全缓解率有限且不影响突变负荷。
  • 异基因造血干细胞移植是唯一可能治愈选项,但并发症和死亡率显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, with an inherent risk for leukemic transformation (~15% over 3-5 years). DIAGNOSIS: Diagnosis is based on the presence of sustained (>3 months) peripheral blood monocytosis (≥1 × 109 /L; monocytes ≥10%), along with bone marrow dysplasia. Clonal cytogenetic abnormalities occur in ~ 30% of patients, while >90% have gene mutations. Mutations involving TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%) and the oncogenic RAS pathway (~30%) are frequent; while the presence of ASXL1 and DNMT3A mutations and the absence of TET2 mutations negatively impact over-all survival. RISK STRATIFICATION: Molecularly integrated prognostic models include; the Groupe Français des Myélodysplasies (GFM), Mayo Molecular Model (MMM) and the CMML specific prognostic model (CPSS-Mol). Risk factors incorporated into the MMM include presence of nonsense or frameshift ASXL1 mutations, absolute monocyte count>10 × 109 /L, hemoglobin <10 g/dL, platelet count <100 × 109 /L and the presence of circulating immature myeloid cells. The MMM stratifies CMML patients into four groups; high (≥3 risk factors), intermediate-2 (2 risk factors), intermediate-1 (1 risk factor) and low (no risk factors), with median survivals of 16, 31, 59 and 97 months, respectively. RISK-ADAPTED THERAPY: Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ~40%-50% and complete remission rates of ~7%-17%; with no impact on mutational allele burdens. Allogeneic stem cell transplant is the only potentially curative option, but is associated with significant morbidity and mortality.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Patnaik MM, Tefferi A. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020. PMID: 31736132. doi:10.1002/ajh.25684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。